Analysis of the plasma proteome in COPD: Novel low abundance proteins reflect the severity of lung remodeling

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 11, Issue 2, 2014, Pages 177-189

  Merali, Salim ^a   Barrero, Carlos A ^a   Bowler, Russell P ^c   Chen, Diane Er ^d   Criner, Gerard ^a   Braverman, Alan ^a   Litwin, Samuel ^b   Yeung, Anthony ^b   Kelsen, Steven G ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

^d Sigma Aldrich Co   (United States)

Author keywords

Biomarkers; COPDgene ; Emphysema

Indexed keywords

BIOLOGICAL MARKER; PLASMA PROTEIN; PROTEOME;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; EMPHYSEMA; ETHNICITY; FEMALE; FORCED EXPIRATORY VOLUME; GEL ELECTROPHORESIS; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SMOKING; TANDEM MASS SPECTROMETRY; AGED; AIRWAY REMODELING; BLOOD; CASE CONTROL STUDY; CAUCASIAN; CLINICAL TRIAL; GENETIC ASSOCIATION; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

AGED; AIRWAY REMODELING; BIOLOGICAL MARKERS; BLOOD PROTEINS; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FORCED EXPIRATORY VOLUME; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; PROTEOMICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84897054418     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2013.831063     Document Type: Article

References (59)

1. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest 2011; 139:165-173.
2. Patel AR, Hurst Jr. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: State of The art. Expert Rev Respir Med 2011; 5: 647-662.
3. Yoshida T, Tuder RM. Pathobiology of cigarette smokeinduced chronic obstructive pulmonary disease. Physiol Rev 2007; 87:1047-1082.
4. Punturieri A, Croxton TL, Weinmann GG, Kiley JP. Chronic obstructive pulmonary disease: A view from The NHLBI. Am J Respir Crit Care Med 2008; 178:441-443.
5. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for The diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532-555.
6. Godtfredsen NS, Lam TH, Hansel TT, Leon ME, Gray N, Dresler C, et al. COPD-related morbidity and mortality after smoking cessation: Status of The evidence. Eur Respir J 2008; 32:844-853.
7. Minino AM, Murphy SL. Death in The United States, 2010; NCHS Data Brief Jul(99):1-8.
8. Ubhi BK, Riley JH, Shaw PA, Lomas DA, Tal-Singer R, MacNee W, et al. Metabolic profi ling detects biomarkers of protein degradation in COPD patients. Eur Respir J 2012; 40:345-355.
9. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J 2008; 31:869-873.
10. Sin DD, Miller BE, Duvoix A, Man SF, Zhang X, Silverman EK, et al. Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 183:1187-1192.
11. Sin DD, Vestbo J. Biomarkers in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009; 6:543-545.
12. Tzortzaki EG, Lambiri I, Vlachaki E, Siafakas NM. Biomarkers in COPD. Curr Med Chem 2007; 14:1037-1048.
13. Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H, et al. Profi ling serum biomarkers in patients with COPD: Associations with clinical parameters. Thorax 2007; 62:595-601.
14. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61:23-28.
15. Devanarayan V, Scholand MB, Hoidal J, Leppert MF, Crackower MA, O'Neill GP, et al. Identifi cation of distinct plasma biomarker signatures in patients with rapid and slow declining forms of COPD. COPD 2010; 7:51-58.
16. Ilumets H, Mazur W, Toljamo T, Louhelainen N, Nieminen P, Kobayashi H, et al. Ageing and smoking contribute to plasma surfactant proteins and protease imbalance with correlations to airway obstruction. BMC Pulm Med 2011; 11:19.
17. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent systemic infl ammation is associated with poor clinical outcomes in COPD: A novel phenotype. PLoS One 2012; 7(5):e37483.
18. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, et al. Infl ammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185:1065-1072.
19. Duvoix A, Dickens J, Haq I, Mannino D, Miller B, Tal-Singer R, et al. Blood fi brinogen as a biomarker of chronic obstructive pulmonary disease. Thorax 2013; 68:670-676.
20. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Infl ammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186:982-988.
21. Verrills NM, Irwin JA, He XY, Wood LG, Powell H, Simpson JL, et al. Identifi cation of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 183:1633-1643.
22. Auff ray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest 2010; 137:1410-1416.
23. Chen H, Wang D, Bai C, Wang X. Proteomics-based biomarkers in chronic obstructive pulmonary disease. J Proteome Res 2010; 9:2798-2808.
24. Patel BB, Barrero CA, Braverman A, Kim PD, Jones KA, Chen DE, et al. Assessment of two immunodepletion methods: Off-Target Effects and variations in immunodepletion effi ciency may confound plasma proteomics. J Proteome Res 2012; 11:5947-5958.
25. Qian WJ, Kaleta DT, Petritis BO, Jiang H, Liu T, Zhang X, et al. Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffi nity separation strategy. Mol Cell Proteomics 2008; 7:1963-1973.
26. Faca V, Pitteri SJ, Newcomb L, Glukhova V, Phanstiel D, Krasnoselsky A, et al. Contribution of protein fractionation to depth of analysis of The serum and plasma proteomes. J Proteome Res 2007; 6:3558-3565.
27. Zhang Q, Faca V, Hanash S. Mining The plasma proteome for disease applicat-ions across seven logs of protein abundance. J Proteome Res 2011; 10:46-50.
28. Qian WJ, Jacobs JM, Liu T, Camp DG, 2nd, Smith RD. Advances and challenges in liquid chromatography-mass spectrometrybased proteomics profi ling for clinical applications. Mol Cell Proteomics 2006; 5:1727-1744.
29. Bandow JE, Baker JD, Berth M, Painter C, Sepulveda OJ, Clark KA, et al. Improved image analysis workfl ow for 2-D gels enables large-scale 2-D gel-based proteomics studies-COPD biomarker discovery study. Proteomics 2008; 8:3030-3041.
30. Rana GS, York TP, Edmiston JS, Zedler BK, Pounds JG, Adkins JN, et al. Proteomic biomarkers in plasma that diff erentiate rapid and slow decline in lung function in adult cigarette smokers with chronic obstructive pulmonary disease (COPD). Anal Bioanal Chem 2010; 397:1809-1819.
31. York TP, van den Oord EJ, Langston TB, Edmiston JS, McKinney W, Webb BT, et al. High-resolution mass spectrometry proteomics for The identifi cation of candidate plasma protein biomarkers for chronic obstructive pulmonary disease. Biomarkers 2010; 15:367-377.
32. Fang Y, Robinson DP, Foster LJ. Quantitative analysis of proteome coverage and recovery rates for upstream fractionation methods in proteomics. J Proteome Res 2010; 9:1902-1912.
33. Ke E, Patel BB, Liu T, Li XM, Haluszka O, Hoff man JP, et al. Proteomic analyses of pancreatic cyst fl uids. Pancreas 2009; 38:e33-42.
34. Xie LQ, Zhao C, Cai SJ, Xu Y, Huang LY, Bian JS, et al. Novel proteomic strategy reveal combined alpha1 antitrypsin and cathepsin D as biomarkers for colorectal cancer early screening. J Proteome Res 2010; 9:4701-4709.
35. Bortner JD, Jr., Richie JP, Jr., Das A, Liao J, Umstead TM, Stanley A, et al. Proteomic profi ling of human plasma by iTRAQ reveals down-regulation of ITI-HC3 and VDBP by cigarette smoking. J Proteome Res 2011; 10:1151-1159.
36. de Torres JP, Casanova C, Pinto-Plata V, Varo N, Restituto P, Cordoba-Lanus E, et al. Gender diff erences in plasma biomarker levels in a cohort of COPD patients: A pilot study. PLoS One. 6(1):e16021.
37. Kim CX, Bailey KR, Klee GG, Ellington AA, Liu G, Mosley ThJr, et al. Sex and ethnic diff erences in 47 candidate proteomic markers of cardiovascular disease: The Mayo Clinic proteomic markers of arteriosclerosis study. PLoS One. 5(2):e9065.
38. Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, Curtis JL, et al. Chronic obstructive pulmonary disease exacerbations in The COPDGene study: Associated radiologic phenotypes. Radiology 2010; 261:274-282.
39. Han Z, Liang CG, Cheng Y, Duan X, Zhong Z, Potireddy S, et al. Oocyte spindle proteomics analysis leading to rescue of chromosome congression defects in cloned embryos. J Proteome Res 2010; 9:6025-6032.
40. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: Visualizing classifi er performance in R. Bioinformatics 2005; 21:3940-3941.
41. Dahl M, Vestbo J, Zacho J, Lange P, Tybjaerg-Hansen A, Nordestgaard BG. C reactive protein and chronic obstructive pulmonary disease: A Mendelian randomisation approach. Thorax 2011; 66:197-204.
42. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:867-874.
43. Haab BB, Geierstanger BH, Michailidis G, Vitzthum F, Forrester S, Okon R, et al. Immunoassay and antibody microarray analysis of The HUPO Plasma Proteome Project reference specimens: Systematic variation between sample types and calibration of mass spectrometry data. Proteomics 2005; 5:3278-3291.
44. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve The prediction of death from cardiovascular causes. N Engl J Med 2008; 358:2107-2116.
45. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: Infl ammation, immunity, and tissue repair and destruction. Eur Respir J 2008; 31:1334-1356.
46. Marciniak SJ, Ron D. Endoplasmic reticulum stress signaling in disease. Physiol Rev 2006; 86:1133-1149.
47. Lawson WE, Cheng DS, Degryse AL, Tanjore H, Polosukhin VV, Xu XC, et al. Endoplasmic reticulum stress enhances fi brotic remodeling in The lungs. Proc Natl Acad Sci USA 2011; 108:10562-10567.
48. Kelsen SG, Duan X, Ji R, Perez O, Liu C, Merali S. Cigarette smoke induces an unfolded protein response in The human lung: A proteomic approach. Am J Respir Cell Mol Biol 2008; 38:541-550.
49. Malhotra D, Thimmulappa R, Vij N, Navas-Acien A, Sussan T, Merali S, et al. Heightened endoplasmic reticulum stress in COPD lungs: The role of Nrf2-regulated proteasomal activity. Am J Respir Crit Care Med 2009; 180:1196-1207.
50. Van Gorp H, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-of-All-Trades and potential target for celldirected therapy. Mol Immunol 2010; 47:1650-1660.
51. Philippidis P, Mason JC, Evans BJ, Nadra I, Taylor KM, Haskard DO, et al. Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: Antiinfl ammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res 2004; 94:119-126.
52. Barnes PJ. Alveolar macrophages as orchestrators of COPD. COPD 2004; 1:59-70.
53. Subramaniam S, Stansberg C, Cunningham C. The interleukin 1 receptor family. Dev Comp Immunol 2004; 28:415-428.
54. Chen R, Li M, Zhang Y, Zhou Q, Shu HB. The E3 ubiquitin ligase MARCH8 negatively regulates IL-1beta-induced NF-kappaB activation by targeting The IL1RAP coreceptor for ubiquitination and degradation. Proc Natl Acad Sci USA 2012; 109:14128-14133.
55. Yang Y, Bin W, Aksoy MO, Kelsen SG. Regulation of interleukin-1beta and interleukin-1beta inhibitor release by human airway epithelial cells. Eur Respir J 2004; 24:360-366.
56. Barnes PJ SS, Pauwels RA. Chronic obstructive pulmonary disease: Molecular and cellular mechanisms. Eur Respir J 2003; 22:672-688.
57. Wang MH, Zhou YQ, Chen YQ. Macrophage-stimulating protein and RON receptor tyrosine kinase: Potential regulators of macrophage infl ammatory activities. Scand J Immunol 2002; 56:545-553.
58. Morrison AC, Wilson CB, Ray M, Correll PH. Macrophagestimulating protein, The ligand for The stem cell-derived tyrosine kinase/RON receptor tyrosine kinase, inhibits IL-12 production by primary peritoneal macrophages stimulated with IFN-gamma and lipopolysaccharide. J Immunol 2004; 172:1825-1832.
59. Ray M, Yu S, Sharda DR, Wilson CB, Liu Q, Kaushal N, et al. Inhibition of TLR4-induced IkappaB kinase activity by The RON receptor tyrosine kinase and its ligand, macrophagestimulating protein. J Immunol 2010; 185:7309-7316.